Search results
Showing 31 to 45 of 8216 results
NICE Listens is our programme of deliberative public engagement. It's used to give us an understanding of public opinion on moral, ethical and social...
All fields marked with * are required and must be filled.
Information for journalists including contact details, FAQS and NICE's stance on key topics.
Role and responsibilities of the National Institute of Health and Care Excellence
We use the best available evidence to develop guidance to improve health and social care. Our guidance takes many forms. From this page, you can find
NICE guidelines are evidence-based recommendations for health and care in England.
Our publication scheme lists all of the information we routinely make available, and where you can find it. We publish most of the information below...
The quality standards advisory committees (QSAC) are independent committees that help to develop our quality standards . Come to a meeting Committee
A new model for evaluating and purchasing antimicrobials in the UK
Antimicrobial resistance (AMR) is an urgent global challenge. It causes around 700,000 deaths each year globally . That number is predicted to rise to
NICE and NHS England announce plan to enable innovative tech to be adopted quicker
NHS patients in England will benefit from faster access to the most innovative and cutting-edge medical technologies under new plans announced today (23 May).
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome (HST31)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity and hyperphagia in Bardet-Biedl syndrome in people 6 years and over, only if they are between 6 and 17 years when treatment starts.
NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA972
Supporting the health and care system to implement virtual wards
Virtual wards (also known as hospital at home) provide hospital level care at home. People on a virtual ward are cared for by a multidisciplinary team
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)
Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.
Evidence-based recommendations on natalizumab (Tysabri) for treating highly active relapsing–remitting multiple sclerosis in adults.
View recommendations for TA127Show all sections